Trademark Overview
On Tuesday, May 18, 2021, a trademark application was filed for HELA 3.0 with the United States Patent and Trademark Office. The USPTO has given the HELA 3.0 trademark a serial number of 90718951. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, October 13, 2022. This trademark is owned by Ultragenyx Pharmaceutical Inc.. The HELA 3.0 trademark is filed in the Chemical Products, Computer & Software Services & Scientific Services, Medical & Beauty Services & Agricultural Services, Personal, and Legal & Social Services categories with the following description:
Chemical, biological, and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, for in vitro laboratory use and in vivo therapeutic use in gene therapy; chemical, biological, and biochemical products for use in the manufacture of pharmaceutical preparations
Licensing of intellectual property
Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic diseases and disorders; providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disorders; medical information services in the nature of providing a database in the field of gene therapy information based on collected patient data and information all for treatment and diagnostic purposes; medical information services
Research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; compiling and sharing of patient data for research purposes in the field of medical science
